0 CHECKOUT

Ischemic Stroke - Pipeline Review, H2 2015

  • ID: 3492371
  • September 2015
  • 277 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AB Science SA
  • AstraZeneca Plc
  • BioTime, Inc.
  • Glialogix, Inc.
  • MediaPharma s.r.l.
  • Pharmicell Co., Ltd.
  • MORE

Ischemic Stroke - Pipeline Review, H2 2015

Summary

The report ‘Ischemic Stroke - Pipeline Review, H2 2015’, provides an overview of the Ischemic Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science SA
  • AstraZeneca Plc
  • BioTime, Inc.
  • Glialogix, Inc.
  • MediaPharma s.r.l.
  • Pharmicell Co., Ltd.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Ischemic Stroke Overview

Therapeutics Development

Pipeline Products for Ischemic Stroke - Overview

Pipeline Products for Ischemic Stroke - Comparative Analysis

Ischemic Stroke - Therapeutics under Development by Companies

Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes

Ischemic Stroke - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Ischemic Stroke - Products under Development by Companies

Ischemic Stroke - Products under Investigation by Universities/Institutes

Ischemic Stroke - Companies Involved in Therapeutics Development

AB Science SA

Acticor Biotech

advanceCor GmbH

Angion Biomedica Corp.

AstraZeneca Plc

Athersys, Inc.

biOasis Technologies Inc.

Biogen, Inc.

BioTime, Inc.

D-Pharm Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Digna Biotech, S.L.

Genervon Biopharmaceuticals, LLC

Glialogix, Inc.

Glucox Biotech AB

Grifols, S.A.

Huons Co., Ltd.

International Stem Cell Corporation

JN-International Medical Corporation

Laboratoires Pierre Fabre SA

Lumosa Therapeutics Co., Ltd.

MediaPharma s.r.l.

Mitsubishi Tanabe Pharma Corporation

Neuralstem, Inc.

Neurotec Pharma SL

NeuroVive Pharmaceutical AB

NoNO, Inc.

Panacea Pharmaceuticals, Inc.

Pharmicell Co., Ltd.

PhytoHealth Corporation

Remedy Pharmaceuticals, Inc.

ReNeuron Group Plc

SanBio, Inc.

Saneron CCEL Therapeutics, Inc.

Simcere Pharmaceutical Group

Stemedica Cell Technologies, Inc.

SynZyme Technologies, LLC

The International Biotechnology Center (IBC) Generium

TikoMed AB

vasopharm GmbH

Vicore Pharma AB

Virogenomics, Inc.

Ischemic Stroke - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

3K3A-APC - Drug Profile

ACT-017 - Drug Profile

alteplase biosimilar - Drug Profile

BB-3 - Drug Profile

BSc-2118 - Drug Profile

C-21 - Drug Profile

Cerecellgram-Stroke - Drug Profile

CNB-001 - Drug Profile

DB-017 - Drug Profile

DM-199 - Drug Profile

Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile

DS-1040 - Drug Profile

GLX-1112 - Drug Profile

glyburide - Drug Profile

GM-602 - Drug Profile

GXNPC-1 - Drug Profile

HBN-1 - Drug Profile

HU-010 - Drug Profile

Human Plasmin - Drug Profile

Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile

ISC-hpNSC - Drug Profile

levomilnacipran hydrochloride ER - Drug Profile

LT-3001 - Drug Profile

Lysimab - Drug Profile

masitinib - Drug Profile

Memantine Nitrone - Drug Profile

Mesenchymal Stem Cells - Drug Profile

MP-124 - Drug Profile

MPHE-001A - Drug Profile

MTfp-siRNA - Drug Profile

MultiStem - Drug Profile

NA-1 - Drug Profile

natalizumab - Drug Profile

NSI-566 - Drug Profile

NTKC-005 - Drug Profile

NVP-014 - Drug Profile

NVX-208 - Drug Profile

PAN-811 - Drug Profile

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile

PHN-014 - Drug Profile

Pinocembrin - Drug Profile

Polyglactin 370 for Ischemic Stroke - Drug Profile

PR-15 - Drug Profile

prasugrel hydrochloride - Drug Profile

Protein for Ischemic Stroke - Drug Profile

Protein for Ischemic Stroke - Drug Profile

Protein for Ischemic Stroke - Drug Profile

Recombinant Peptide for Ischemic Stroke - Drug Profile

Recombinant Plasmin - Drug Profile

Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia - Drug Profile

Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile

ReN-001 - Drug Profile

RTL-551 - Drug Profile

SB-623 - Drug Profile

SIM-071201 - Drug Profile

Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile

Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile

Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile

Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile

Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile

Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile

SMTP-7 - Drug Profile

StromAb - Drug Profile

T-33 - Drug Profile

TF-0023 - Drug Profile

THR-18 - Drug Profile

ticagrelor - Drug Profile

TM-700 - Drug Profile

TPAi-14 - Drug Profile

TPAi-23 - Drug Profile

TS-01 - Drug Profile

TXA-127 - Drug Profile

TXA-302 - Drug Profile

UCCB-01144 - Drug Profile

Vaccine to Target NMDAR1 for Ischemic Stroke - Drug Profile

VACNO - Drug Profile

VAS-2870 - Drug Profile

Ischemic Stroke - Recent Pipeline Updates

Ischemic Stroke - Dormant Projects

Ischemic Stroke - Discontinued Products

Ischemic Stroke - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Ischemic Stroke, H2 2015

Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Number of Products under Development by Companies, H2 2015 (Contd..2)

Number of Products under Development by Companies, H2 2015 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Development by Companies, H2 2015 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2015

Ischemic Stroke - Pipeline by AB Science SA, H2 2015

Ischemic Stroke - Pipeline by Acticor Biotech, H2 2015

Ischemic Stroke - Pipeline by advanceCor GmbH, H2 2015

Ischemic Stroke - Pipeline by Angion Biomedica Corp., H2 2015

Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2015

Ischemic Stroke - Pipeline by Athersys, Inc., H2 2015

Ischemic Stroke - Pipeline by biOasis Technologies Inc., H2 2015

Ischemic Stroke - Pipeline by Biogen, Inc., H2 2015

Ischemic Stroke - Pipeline by BioTime, Inc., H2 2015

Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2015

Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2015

Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2015

Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015

Ischemic Stroke - Pipeline by Glialogix, Inc., H2 2015

Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2015

Ischemic Stroke - Pipeline by Grifols, S.A., H2 2015

Ischemic Stroke - Pipeline by Huons Co., Ltd., H2 2015

Ischemic Stroke - Pipeline by International Stem Cell Corporation, H2 2015

Ischemic Stroke - Pipeline by JN-International Medical Corporation, H2 2015

Ischemic Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2015

Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015

Ischemic Stroke - Pipeline by MediaPharma s.r.l., H2 2015

Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015

Ischemic Stroke - Pipeline by Neuralstem, Inc., H2 2015

Ischemic Stroke - Pipeline by Neurotec Pharma SL, H2 2015

Ischemic Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2015

Ischemic Stroke - Pipeline by NoNO, Inc., H2 2015

Ischemic Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015

Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2015

Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2015

Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015

Ischemic Stroke - Pipeline by ReNeuron Group Plc, H2 2015

Ischemic Stroke - Pipeline by SanBio, Inc., H2 2015

Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015

Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2015

Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2015

Ischemic Stroke - Pipeline by SynZyme Technologies, LLC, H2 2015

Ischemic Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015

Ischemic Stroke - Pipeline by TikoMed AB, H2 2015

Ischemic Stroke - Pipeline by vasopharm GmbH, H2 2015

Ischemic Stroke - Pipeline by Vicore Pharma AB, H2 2015

Ischemic Stroke - Pipeline by Virogenomics, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2015

Ischemic Stroke - Dormant Projects, H2 2015

Ischemic Stroke - Dormant Projects (Contd..1), H2 2015

Ischemic Stroke - Dormant Projects (Contd..2), H2 2015

Ischemic Stroke - Dormant Projects (Contd..3), H2 2015

Ischemic Stroke - Dormant Projects (Contd..4), H2 2015

Ischemic Stroke - Discontinued Products, H2 2015

Ischemic Stroke - Discontinued Products (Contd..1), H2 2015

Ischemic Stroke - Discontinued Products (Contd..2), H2 2015

List of Figures

Number of Products under Development for Ischemic Stroke, H2 2015

Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AB Science SA
Acticor Biotech
advanceCor GmbH
Angion Biomedica Corp.
AstraZeneca Plc
Athersys, Inc.
biOasis Technologies Inc.
Biogen, Inc.
BioTime, Inc.
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Genervon Biopharmaceuticals, LLC
Glialogix, Inc.
Glucox Biotech AB
Grifols, S.A.
Huons Co., Ltd.
International Stem Cell Corporation
JN-International Medical Corporation
Laboratoires Pierre Fabre SA
Lumosa Therapeutics Co., Ltd.
MediaPharma s.r.l.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
Neurotec Pharma SL
NeuroVive Pharmaceutical AB
NoNO, Inc.
Panacea Pharmaceuticals, Inc.
Pharmicell Co., Ltd.
PhytoHealth Corporation
Remedy Pharmaceuticals, Inc.
ReNeuron Group Plc
SanBio, Inc.
Saneron CCEL Therapeutics, Inc.
Simcere Pharmaceutical Group
Stemedica Cell Technologies, Inc.
SynZyme Technologies, LLC
The International Biotechnology Center (IBC) Generium
TikoMed AB
vasopharm GmbH
Vicore Pharma AB
Virogenomics, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx